Pneumothorax in Tertiary Intensive Care With COVID-19 is Associated With Increased Mortality

serife gökbülbüt bektaş (serifegbektas@gmail.com)
Ankara City Hospital Ankara

Demet Bölükbaşı
Ankara Yıldırım Beyazıt University

Baha Burak Konak
Ankara Yıldırım Beyazıt University

Ahmet Gökhan Akdağ
Ankara City Hospital Ankara

Aydan Çalışkan
Ankara City Hospital Ankara

Seval İzdeş
Ankara Yıldırım Beyazıt University

Research Article

Keywords: COVID-19, SARS-CoV 2, Epidemiology, Mortality, Pneumothorax, ARDS

DOI: https://doi.org/10.21203/rs.3.rs-520318/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: To examine the laboratory findings with clinical characteristics and treatments of patients who were hospitalized in a tertiary intensive care unit with the diagnosis of COVID-19 and developed pneumothorax and to determine epidemiology and risks of pneumothorax.

Methods: The study was conducted by retrospectively examining the electronic records of 681 COVID-19 patients who were followed up between 1 April 2020 and 1 January 2021 in 3 tertiary care units (each was 24 beds). Patients demographic and clinical characteristics, laboratory findings, mechanical ventilator parameters and chest imaging were collected retrospectively.

Results: Pneumothorax in 22 (3.2%) of 681 with COVID-19 patients were detected and ARDS in 481 (70.6). All the study patients met ARDS diagnostic criterias. Mortality rates were 43.4% (296/681) in all patients, 52.8% (254/481) in patients with ARDS, and 86.3% (19/22) in patients with pneumothorax. Pneumothorax occurred in the patients within a mean of 17.4 ± 4.8 days. The computed tomographies of patients were observed common ground-glass opacities, heterogenic distribution with patch infiltrates, alveolar exudates, interstitial thickening in the 1st week of their follow-up.

Conclusion: We observed that pneumothorax significantly increased mortality in COVID-19 patients with ARDS. We believe that understanding and preventing the characteristics of pneumothorax will make an important contribution to mortality reduction.

Introduction

The frequency of pneumothorax occurrence due to COVID-19 in the first series has been reported to be between 1–2% [1–3]. The literature published subjecting pneumothorax in COVID-19 patients with ARDS are mostly case reports or case series [4–6]. Among the reported series, the number of cases was high only in a multi-center study, but the patients included were not intubated [7]. While pneumothorax in ARDS patients varied between 1.5–77% in previous publications, pneumothorax was reported as 10% in COVID-19 related ARDS [4, 8–10]. Both the reported case series and the number of cases was deficient, especially in critically ill patients [4]. Experience on this matter needed to be published.

Herein, we report the largest case series with the diagnosis of COVID-19 related pneumothorax in single center tertiary intensive care units and describe their clinical characteristics and outcomes. These results may shed light on preventing pneumothorax by early diagnosis in critically ill patients, and mortality can be reduced.

Methods

This study was approved by the Local Ethics Committee and conducted with the method of retrospective screening of 681 coronavirus disease (COVID-19) patients hospitalized between April 2020 and January 2021 in the tertiary care unit of the Ankara City General Hospital. Laboratory-confirmed COVID-19 patients (with real time reverse transcription-polymerase reaction; RT-PCR) older than 18 years who were followed by ICU and developed a pneumothorax (with/without pneumomediastinum or subcutaneous emphysema) during the course were included in the study. Patients who had pneumothorax for any reason without COVID-19 were excluded from the study.

Patients demographics, comorbidities, and APACHE II scores, laboratory tests [complete blood count, biochemical and coagulation tests, C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6) levels] and outcomes were
recorded. Diagnosis of ARDS was based on Berlin standards. Invasive procedures and all respiratory and mechanical ventilator parameters prior to barotrauma were recorded. X-ray and chest CT scans of all patients were examined. Initial chest CT was taken in all patients between the 1st and the 7th day after hospitalization. The follow-up of the patients was usually performed with a portable X-ray.

**Statistical Analysis**

Statistical analyses were performed using the SPSS software (version; 15 SSPSS Inc. Chicago) for windows. All variables were checked for normal distribution. Variables were reported as mean and standard deviation or as median when appropriate. Continuous variables were compared with Student's t-test or the Mann-Whitney U test. The chi-square test was used to test for proportions. A p-value of $\leq 0.05$ was considered as statistically significant.

**Results**

A total of 681 patients were followed up in the ICU with the diagnosis of COVID-19 and 296 (43.4%) of them died during their follow-up and 481 (%70.6) of them patients met ARDS diagnostic criterias. The mortality of ARDS patients was 254 (52.8%). The overall incidence of pneumothorax was 3.2% (22/681), 4.5% (22/481) in patients with ARDS. Nineteen of the 22 patients died during hospitalization, with a mortality as high as 86.3 % (19/22). In 3 of 22 patients with pneumothorax, pneumomediastinum was seen subcutaneous emphysema in 5. All patients who developed pneumothorax were treated with invasive mechanical ventilation (Fig. 1).

Twenty-two of patients with pneumothorax met the diagnostic criteria of ARDS. A total of 22 patients, including 16 (72.7%) males and 6 (27.3%) females, were included in the study. The mean age of the patients was 64.6 ± 10.1 (range: 48–85) years. Comorbidities accompanying pneumothorax were type 2 diabetes mellitus in 9 (40.9%), hypertension in 9 (40.9%), cancer in 2 (9.1%), asthma in 1 (4.5%), chronic renal failure in 1 (4.5%), and coronary artery disease in 1 (4.5%), whereas there were no comorbidities in 4 (18.2%) patients. The study population had an APACHE II score of 18.9 ± 8.3 (Table 1).
Table 1  
The Clinical Characteristics of Patients  

|                          | n = 22 patients |
|--------------------------|-----------------|
| **Age, years (mean ± SD)** | 64.6 ± 9.7      |
| **Sex, Male/Female (%)**  | 16/6 (72.7/27.3) |
| **APACHE (mean ± SD)**    | 18.9 ± 8.3.     |
| **Comorbidities (%)**     |                 |
| Type 2 diabetes mellitus  | 9 (40.9)        |
| Hypertension              | 9 (40.9)        |
| Cancer                    | 2 (9.1)         |
| Asthma                    | 1 (4.5)         |
| Chronic renal failure     | 1 (4.5)         |
| Coronary artery disease   |                 |
| **Time, days (mean ± SD)**|                |
| Admitted to the ICU       | 8 ± 2.6         |
| Start to Invasive Mechanical Ventilation | 9.1 ± 3.4 |
| On the day of pneumothorax occurrence | 17.4 ± 4.8 |
| Length of Stay of ICU     | 42.9 ± 22.3     |

The mean duration of admission to ICU was 8 ± 2.6 (3–14) days in the patients with pneumothorax. The duration of started to invasive mechanical ventilation was 9.1 ± 3.4 (3–18) days. Pneumothorax occurred in the patients within a mean of 17.4 ± 4.8 (7–29) days. Length of Stay of ICU in the patients with pneumothorax was 42.9 ± 22.3 (16–119) days (Table 1).

The median CRP level was found to be 65 mg/L (range: 22–180) on the 1st day of hospitalization to the ICU, and 105 mg/L (range: 39–250) on the day of pneumothorax occurrence. The difference was statistically significant (p < 0.05). The median lymphocyte count in the study group on the 1st day of ICU was 500 /µL with a (range: 260–680), and the median lymphocyte count on the day of pneumothorax occurrence was significantly lower 360/µL (range: 70–650) (p < 0.05). At the ICU 1st day, the median neutrophil/lymphocyte rate was 20.4 (range:7.2–44.3), the median fibrinogen level was 3.2 g/L (range:0.86–6.2), the median LDH value was 447 U/L (range:268–744), while on the day of pneumothorax occurrence, the median neutrophil/lymphocyte rate was 23.7 (range:8.2-114.5), the median fibrinogen level was 4.68 g/L (range:1.25–7.74), the median LDH value was 513 U/L (range:280–2259). These increases were statistically significant (Table 2).
Table 2
Comparison of the laboratory findings

|                      | Median    | Minimum | Maximum | p     |
|----------------------|-----------|---------|---------|-------|
| CRP_A                | 65 mg/L   | 22      | 180     | 0.001 |
| CRP_B                | 105 mg/L  | 39      | 250     |       |
| Lymphocyte_A         | 500 /µL   | 260     | 680     | 0.001 |
| Lymphocyte_B         | 360 /µL   | 70      | 650     |       |
| N/L Rate_A           | 20.4      | 7.2     | 44.3    | 0.001 |
| N/L Rate_B           | 23.7      | 8.2     | 114.5   |       |
| Fibrinogen_A         | 3.2 g/L   | 0.86    | 6.2     | 0.001 |
| Fibrinogen_B         | 4.68 g/L  | 1.25    | 7.74    |       |
| D-dimer_A            | 3.4 mg/L  | 0.8     | 32.4    | 0.035 |
| D-dimer_B            | 4.8 mg/L  | 0.6     | 35.2    |       |
| IL-6_A               | 16.4 pg/mL| 3.1     | 39.6    | 0.036 |
| IL-6_B               | 21 pg/mL  | 2       | 48.8    |       |
| Procalcitonin_A      | 0.2 ng/mL | 0.01    | 6.03    | 0.41  |
| Procalcitonin_B      | 0.1 ng/mL | 0.02    | 3.02    |       |
| LDH_A                | 447 U/L   | 268     | 744     | 0.016 |
| LDH_B                | 513 U/L   | 280     | 2259    |       |
| Troponin T_A         | 24 ng/mL  | 6       | 320     | 0.053 |
| Troponin T_B         | 18 ng/mL  | 4       | 628     |       |

A: Start to Invasive Mechanical Ventilation ; B: on the day of pneumothorax occurrence

When the patients were evaluated regarding mechanical ventilator parameters, the median Positive end-expiratory pressure (PEEP) was 6 cm H₂O (range: 5–9) on ICU 1st day, and the median was 7 cm H₂O (range: 5–9) on the day of pneumothorax occurrence. Yet, at the ICU 1st day, the median Peak inspiratory pressure (PIP) was 29 cm H₂O (range:27–32), median tidal volume (Vₜ) was 400 ml (range:320–500), while on the day of pneumothorax occurrence, median PIP was 29 cm H₂O (range:27–32), and median tidal volume was 380 ml (range: 340–500). The difference between the respiratory parameters between the 1st day of ICU hospitalization and the day of pneumothorax occurrence was not statistically significant (Table 3). The computed tomographies of patients were observed common ground-glass opacities, heterogenic distribution with patch infiltrates, alveolar exudates, interstitial thickening in the 1st week of their follow-up. All CT findings and clinical summaries of the patients are given in Table 4 (Table 4). Thorax CT images are shown in Figs. 2 and 3 (Fig. 2, 3).
Table 3  
Evaluations of mechanical ventilator parameters

| Median          | Minimum | Maximum | p    |
|-----------------|---------|---------|------|
| PEEP_A          | 6 cm H₂O| 5       | 9    | 0.059|
| PEEP_B          | 7 cm H₂O| 5       | 9    |      |
| PIP_A           | 29 cm H₂O| 27     | 32   | 0.6  |
| PIP_B           | 29 cm H₂O| 27     | 32   |      |
| Tidal volume    | 400 ml  | 320     | 500  | 0.031|
| Tidal volume    | 380 ml  | 340     | 500  |      |

**A**: Start to Invasive Mechanical Ventilation; **B**: on the day of pneumothorax occurrence; **PIP**: Peak inspiratory pressure; **PEEP**: Positive end-expiratory pressure

During the treatment, high dose methylprednisolone was administered to the patients with pneumothorax for a total of 7 days, with a loading dose of 1 g/day for three days. The dose given after loading dose was 80 mg/day for two days, and then 40 mg/day for two days. A chest tube was inserted into all patients, except five patients who developed subcutaneous emphysema. Twentytwo patients were treated with invasive mechanical ventilator.

**Table 4.** All findings and clinical summaries of the patients
| No | Sex/Age (years) | Comorbidity                        | Admitted to the ICU | On the day of pneumothorax occurrence | CT Findings                                                                 | Chest Drain | Outcome | Length of hospital stay, days |
|----|----------------|------------------------------------|---------------------|---------------------------------------|-----------------------------------------------------------------------------|-------------|---------|------------------------------|
| 1  | M/,68          | Cancer                             | 9                   | 26                                    | Bilateral patchy ground-glass opacities, peripheral, more prominent in the lower lobes | Yes         | exitus  | 42                           |
| 2  | M/ 64          | -                                  | 6                   | 29                                    | Diffuse ground-glass opacities, Central and peripheral, intralobular septal thickening | Yes         | exitus  | 47                           |
| 3  | M/85           | Coronary artery disease            | 11                  | 19                                    | Bilateral ground-glass opacities, central and peripheral, septal thickening  | Yes         | exitus  | 31                           |
| 4  | M/68           | Hypertension, Diabetes             | 8                   | 14                                    | Bilateral ground-glass opacities, central and peripheral, crazy-paving pattern, interseptal thickening | Yes         | exitus  | 19                           |
| 5  | M,61           | -                                  | 14                  | 23                                    | Bilateral Diffuse ground-glass opacities, Peripheral                        | Yes         | exitus  | 119                          |
| 6  | M ,54          | -                                  | 7                   | 20                                    | Bilateral patchy ground-glass opacities, peripheral                         | Yes         | exitus  | 27                           |
| 7  | F/64           | Asthma                             | 7                   | 15                                    | Bilateral ground-glass opacities, Peripheral,                              | Yes         | exitus  | 35                           |
| 8  | F/68           | Hypertension, Diabetes             | 10                  | 17                                    | Bilateral glass-ground opacification, peripheral, multifocal                | Yes         | exitus  | 22                           |
| No. | Gender | Age (yr) | Disease | Comorbidities | Chest CT Findings | Survival Status | Exitus |
|-----|--------|----------|---------|---------------|------------------|-----------------|--------|
| 9   | M      | 69       | Hypertension | Diabetes | Diffuse ground-glass opacities, central and peripheral | No | exitus | 55 |
| 10  | F      | 71       | Hypertension |         | Bilateral glass-ground opacification, peripheral | Yes | exitus | 56 |
| 11  | F      | 55       | Diabetes |         | Bilateral patchy ground-glass opacities, peripheral, more prominent in the peripheral | Yes | exitus | 86 |
| 12  | M      | 50       |        |         | Bilateral alveolar ground glass opacities, peripheral, more prominent in the peripheral and subpleural areas | Yes | exitus | 31 |
| 13  | M      | 77       | Chronic renal failure |         | Bilateral ground-glass opacities, central and peripheral, crazy-paving pattern, interseptal thickening | Yes | exitus | 36 |
| 14  | M      | 58       | Hypertension |         | Bilateral glass-ground opacification, peripheral | Yes | exitus | 46 |
| 15  | M      | 68       | Cancer |         | Bilateral ground-glass opacities, central and peripheral, crazy-paving pattern | Yes | exitus | 34 |
| 16  | M      | 51       | Hypertension, Diabetes |         | Bilateral glass-ground opacification, peripheral | No | exitus | 16 |
| 17  | F      | 80       | Hypertension, Diabetes |         | Bilateral patchy ground-glass opacities, | No | exitus | 40 |
peripheral crazy-paving pattern, interseptal thickening

| No. | Sex | Age | Diabetes | Hypertension | Pneumothorax Pattern | Exitus | Discharge | Days |
|-----|-----|-----|----------|--------------|----------------------|--------|-----------|------|
| 18  | M/48| 10  | 14       | Bilateral    | No                   | exitus | 42        |
| 19  | F/63| 9   | 18       | Bilateral    | exitus               | 44     |
| 20  | M/73| 6   | 13       | Bilateral    | No                   | discharge | 38 |
| 21  | M/69| 5   | 16       | Bilateral    | Yes                  | discharge | 42 |
| 22  | M/58| 4   | 17       | Bilateral    | Yes                  | discharge | 37 |

**Discussion**

Pneumothorax is a fatal complication in patients with ARDS, especially those undergoing invasive mechanical ventilation [11]. In a previous study in which 84 severe ARDS patients were examined, the pneumothorax rate was 48.8%, and the mortality (66% vs 46%) was higher in patients with pneumothorax [12]. In the presence of COVID-19 and ARDS, this rate was found to be 80% [4]. Since our intensive care is one of our country’s reference centers, severe patients were accepted from other intensive care units and hospitals. Hence, our mortality rate was 43.4% in all patients, 52.8% in patients with ARDS. This rate was found as 87% in the case of pneumothorax with ARDS occurrence. Therefore, we believe that preventing pneumothorax in a tertiary intensive care unit will significantly reduce mortality rates.

In a case series conducted on SARS patients in Hong Kong, it was observed that high neutrophil count and LDH level increased the tendency to pneumothorax [9]. It was also thought that high-dose methylprednisolone administration affected the improvement of the lung tissue and contributed to the pneumothorax occurrence [9]. Hameed et al. reported that high LDH and acute phase reactants were higher in COVID-19 patients who received high-dose prednisolone and developed pneumothorax [13]. We used high dose methylprednisolone in all our patients. We found a significant difference between the baseline LDH level of our patients and the LDH levels at the time of pneumothorax occurrence. In the same manner, we observed that acute phase reactants increased significantly. Increases in acute phase reactants and LDH may be an early indicator for pneumothorax. Besides, we think that it would be beneficial to reconsider high-dose methylprednisolone treatment in this respect in the patient group requiring intensive care.
The duration of ARDS can explain the incidence of pneumothorax in ARDS. ARDS consists of three phases: exudative phase (1–7 days), proliferative phase (8–21 days), and fibrotic phase (> 21 days) [14]. Gattinoni L et al. found the incidence of pneumothorax in late ARDS (longer than two weeks) patients as 87% and early ARDS (less than seven days) as 30% [11]. Wang et al. reported that pneumothorax occurred two weeks after symptom onset in 5 COVID-19 patients with ARDS [4]. In line with the literature, we found that pneumothorax's occurrence time was 17.4 ± 4.8 days in our patients. We did not find a significant relationship between pneumothorax occurrence time and mortality.

ARDS development is one of the most important prognostic factors in COVID-19 patients. In ARDS pathophysiology, neutrophil count is characterized by increased activation of proinflammatory cytokines and complement cascade, which results in microvascular permeability and fluid exudation [15]. Eventually, fluid accumulation, alveolar atelectasis, and fibrin accumulation are seen in the lung [15]. The occurrence of pneumothorax in mechanically ventilated patients is closely related to the underlying pulmonary patholgy, and ARDS has been proven to be closely related to the occurrence of this complication [16]. As it has been marvelously described by computed tomographic studies in patients with ARDS, the affected lung parenchyma, seems to have a remarkable heterogenic distribution which causes a multi-compartmental lung, with patchy infiltrates interspersed with normal-appearing lung areas [11]. We performed tomography on our patients in the 1st week of their follow-up (table 4, Fig. 1–2). As seen in the literature, we observed common ground-glass opacities, heterogenic distribution with patchy infiltrates, alveolar exudates in our patients' tomographic images. Interstitial thickening was observed in patients, although the computed tomography was performed in the early period. Emphysematous appearance and bullous formations occur in the affected lung areas in the late period, explaining the increase in pneumothorax incidence in this period [10].

Patients with ARDS who are under mechanical ventilation are at the highest risk for pneumothorax development [11]. Many ventilation parameters, such as tidal volume, PIP, PEEP, and respiratory rate are considered important in the development of barotrauma. It was shown that there is a high correlation between the development of end-inspiratory pressure \( P_{\text{plat}} \), especially when exceeding 35 cm H\(_2\)O and pneumothorax [17]. Furthermore, large tidal volume might elicit injury to the pulmonary epithelium; therefore tidal volume reduction is another parameter presented for the prevention of ventilator-induced injury in ARDS [18]. \( P_{\text{plat}} \) pressure did not exceed 35 cm H\(_2\)O in the patients we followed up. \( P_{\text{plat}} \) pressure was aimed to be kept below 30 cm H\(_2\)O, and only four patients were observed to have over 30 cm H\(_2\)O pressure at the time of pneumothorax occurrence. Also, \( V_T \) was aimed to be kept between 4–6 ml/kg to prevent pulmonary epithelium damage. Neuromuscular blockers and fentanyl were used to minimize oxygen consumption and provide lung-protective settings. High PEEP levels are associated with the persistence of lung air leaks as well as the occurrence of pneumothorax. PEEP level was kept at 5–9 cm H\(_2\)O level in our patients. In conclusion, we applied AC protective ventilation in almost all ARDS patients who developed pneumothorax in ICU, but we still could not avoid pneumothorax occurrence.

Data on pneumothorax treatment in ARDS patients are limited. Tube thoracostomy, open thoracotomy, pleurodesis, and thoracoscopic surgical methods are among the treatment methods. It was shown in the previous studies that thoracotomy increases mortality in patients with ARDS [19]. A limited number of successful results have been published using thoracoscopic surgical methods, but further studies are needed on this subject [20]. We placed chest tubes in all of our patients during the treatment, except for five patients with subcutaneous emphysema together with pneumothorax. Also, ECMO was used in one severe ARDS patient whose oxygenation could not be achieved. The patient's survival time who had diffuse lung involvement was extended, but mortality could not be avoided. Nevertheless, we think that administering ECMO can be one of the most promising options in patients who develop...
ARDS and pneumothorax due to COVID-19 since it reduces lung effort and provides a time gap for the treatment of pneumothorax and the elimination of the virus.

This study had some limitations. The study was conducted retrospectively, and further studies may fill some of the deficiencies of this study. First of all, the number of patients was limited. A multi-center study with a larger sample size may contribute to treatment improvement. Second, the risk factors can be compared by expanding the study population with patients who do not require intensive care conditions, who do not have ARDS, and who have a milder manifestation. Third, since it is difficult to use CT scan as an imaging method in the patients' follow-up, bedside X-ray criteria or USG administration methods can be defined for follow-up. Besides, it can be discussed to administer early treatment to patients to reduce mortality. Also, the relationship between high-dose methylprednisolone treatment and pneumothorax can be examined.

In conclusion, although lung-protective ventilation parameters were applied, we found that mortality was high in our COVID-19 patients with ARDS. We have seen that the pneumothorax tendency was more common in patients after two weeks. We also observed that acute phase reactants and LDH increased significantly on the day of pneumothorax occurrence. According to our findings, pneumothorax with ARDS increased mortality, and we believe that the prevention of pneumothorax will make an important contribution to reducing mortality. Therefore, more comprehensive studies are needed on this subject in the future to prevent and treatment pneumothorax occurrence in critically ill COVID-19 patients.

**Abbreviations**

APACHE: Acute Physiology and Chronic Health Evaluation; ARDS: Acute Respiratory Distress Syndrome; COVID-19: Coronavirus Disease; CRP: C-reaktif protein; IL-6: interleukin-6; LDH: Lactate Dehydrogenase; PCT: procalcitonin; PEEP: Positive end-expiratory pressure; PIP: Peak inspiratory pressure; P(plat): End-inspiratory pressure; $V_T$: Median Tidal Volume

**Declarations**

**Disclosures**

None.

**Ethic Declarations**

**Ethics approval and consent to participate**

Written informed consent was obtained either from the participants (if alive) or their relatives (if dead) because of the unprecedented situation (COVID-19 pandemic) and in this informed consent, it is clearly stated that the data may be used in retrospective studies anonymously. Then this study was approved by the Local Ethics Committee. Ankara City General Hospital (Number: E2-21-105)

**Consent for publication**

Not applicable.

**Availability of data and materials**
The datasets during the current study available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**

No funding was received

**Authors’ contributions**

SGB carried out the design of the study, Data collection &/or processing, writing, performed the statistical analysis and drafted the manuscript. DB, AÇ carried out the literature search. BBK participated in the sequence alignment. AGA participated in the design of the study. SI conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable

**References**

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020: 395(10223): 507–13. doi: 10.1016/S0140-6736(20)30211-7.

2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8: 475–81. doi: 10.1016/S2213-2600(20)30079-5.

3. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 2020 Nov;92(11):2511–2515. doi: 10.1002/jmv.25891.

4. Wang XH, Duan J, Han X, Liu X, Zhou J, Wang X, et al. High incidence and mortality of pneumothorax in critically ill patients with COVID-19. Heart Lung. 2021;50:37–43. doi: 10.1016/j.hrtlng.2020.10.002.

5. Shan S, Guangming L, Wei L, Xuedong Y. Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19: case report and literature review. Rev Inst Med Trop Sao Paulo. 2020 Oct 9;62:e76. doi: 10.1590/S1678-994620202062076.

6. Dennison J, Carlson S, Faehling S, Lieb M, Mubarik A. Case report: Spontaneous pneumothorax in resolved, uncomplicated COVID-19 Pneumonia-A literature review. Respir Med Case Rep. 2020;31:101291. doi: 10.1016/j.rmcr.2020.101291.

7. Martinelli AW, Ingle T, Newman J, et al. COVID-19 and pneumothorax: a multicentre retrospective case series. Eur Respir J. 2020; 56:2002697. doi: 10.1183/13993003.02697-2020.

8. Woodringer JH. Pulmonary interstitial emphysema in the adult respiratory distress syndrome. Crit Care Med. 1985;13:786–91. http://doi.org/10.1097/00003246-198510000-00003.

9. Sihoe AD, Wong RH, Lee AT, et al. Severe acute respiratory syndrome complicated by spontaneous pneumothorax. Chest. 2004;125:2345–51. doi: 10.1378/chest.125.6.2345.
10. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010;303:865–73. doi: 10.1001/jama.2010.218.

11. Terzi E, Zarogoulidis K, Kougiontzis I, Dryllis G, Kioumis I, Pitsiou et al. Acute respiratory distress syndrome and pneumothorax. J Thorac Dis. 2014;6:S435-42. doi: 10.3978/j.issn.2072-1439.2014.08.34.

12. Gattinoni L, Bombino M, Pelosi P, et al. Lung structure and function in different stages of severe adult respiratory distress syndrome. JAMA. 1994;271:1772–9.

13. Hameed M, Jamal W, Yousaf M, Thomas M, Haq IU, Ahmed S, et al. Pneumothorax In Covid-19 Pneumonia: A case series. Respir Med Case Rep. 2020;31:101265. doi: 10.1016/j.rmcr.2020.101265.

14. Tomashefski Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med. 2000;21:435–66. doi: 10.1016/s0272-5231(05)70158-1.

15. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–49. doi: 10.1056/NEJM200005043421806.

16. Gammon RB, Shin MS, Groves RH Jr, Hardin JM, Hsu C, Buchalter SE. Clinical risk factors for pulmonary barotrauma: a multivariate analysis. Am J Respir Crit Care Med. 1995;152:1235–40. doi: 10.1164/ajrccm.152.4.7551376.

17. Camporota L, Hart N. Lung protective ventilation. BMJ. 2012;344:e2491. doi: 10.1136/bmj.e2491.

18. Finfer S, Rocker G. Alveolar overdistension is an important mechanism of persistent lung damage following severe protracted ARDS. Anaesth Intensive Care. 1996;24:569–73. doi: 10.1177/0310057X9602400511.

19. Wagner PK, Knoch M, Sangmeister C, Müller E, Lennartz H, Rothmund M. Extracorporeal gas exchange in adult respiratory distress syndrome: associated morbidity and its surgical treatment. Br J Surg. 1990;77:1395–8. doi: 10.1002/bjs.1800771224.

20. Huang J, Li H, Chen S, Lan C, Lin Q, Weng H. First successful combination of extracorporeal membrane oxygenation (ECMO) with video-assisted thoracic surgery (VATS) of pulmonary bullae resection in the management of refractory pneumothorax in a critically ill patient with H7N9 pneumonia and acute respiratory distress syndrome: A case report. Medicine (Baltimore). 2019;98:e15661. doi: 10.1097/MD.0000000000015661.

Figures
Figure 1

Mortality rates
Figure 2

Thorax CT images of patients from 1 to 12
Figure 3

Thorax CT images of patients from 13 to 22